- Home
- XTKG vs CTOR Comparison
XTKG vs CTOR Comparison
Compare XTKG & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- CTOR
- Stock Information
- Founded
- XTKG 1997
- CTOR 2021
- Country
- XTKG Singapore
- CTOR United States
- Employees
- XTKG N/A
- CTOR N/A
- Industry
- XTKG
- CTOR
- Sector
- XTKG
- CTOR
- Exchange
- XTKG NYSE
- CTOR NYSE
- Market Cap
- XTKG 63.1M
- CTOR 63.7M
- IPO Year
- XTKG 2019
- CTOR N/A
- Fundamental
- Price
- XTKG $1.80
- CTOR $1.97
- Analyst Decision
- XTKG
- CTOR Buy
- Analyst Count
- XTKG 0
- CTOR 2
- Target Price
- XTKG N/A
- CTOR $6.00
- AVG Volume (30 Days)
- XTKG 59.6K
- CTOR 3.1M
- Earning Date
- XTKG 08-05-2025
- CTOR 08-11-2025
- Dividend Yield
- XTKG N/A
- CTOR N/A
- EPS Growth
- XTKG N/A
- CTOR N/A
- EPS
- XTKG N/A
- CTOR N/A
- Revenue
- XTKG $11,611,442.00
- CTOR N/A
- Revenue This Year
- XTKG N/A
- CTOR N/A
- Revenue Next Year
- XTKG N/A
- CTOR N/A
- P/E Ratio
- XTKG N/A
- CTOR N/A
- Revenue Growth
- XTKG N/A
- CTOR N/A
- 52 Week Low
- XTKG $0.53
- CTOR $0.55
- 52 Week High
- XTKG $9.40
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- XTKG 54.02
- CTOR N/A
- Support Level
- XTKG $1.73
- CTOR N/A
- Resistance Level
- XTKG $1.90
- CTOR N/A
- Average True Range (ATR)
- XTKG 0.15
- CTOR 0.00
- MACD
- XTKG -0.00
- CTOR 0.00
- Stochastic Oscillator
- XTKG 73.53
- CTOR 0.00
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries. It generates revenue from service lines: Application development services; Consulting and technical support services; Subscription services; Trading; and Others, of which maximum revenue is derived from Application development services. Geographically, all of the company's revenue is derived from PRC.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.